Journal of Medical Case Reports · 2016 · 28 citations · 9 references
MedicineNeurologyPharmacotherapyImmunotherapyMonoclonal AntibodiesNeurologic PharmacotherapyAcute Ischemic StrokeAcute Stroke ManagementAntithrombotic TherapyCerebrovascular DiseaseStrokeThrombolytic TherapyAcute Ischemic Stroke InterventionAcute Ischemic Stroke ManagementAcute Ischemic Stroke ThrombolysisAcute Ischemic Stroke TreatmentIdarucizumab ReversalPlasminogen ActivatorsSevere AphasiaThrombolysis In Ischemic Stroke
BACKGROUND: Effective anticoagulation routinely precludes patients from receiving intravenous thrombolysis with recombinant tissue plasminogen activator to reverse severe symptoms of ischemic stroke. We report what we believe to be the first case of ischemic stroke successfully treated with recombinant tissue plasminogen activator after antagonizing dabigatran with the monoclonal antibody idarucizumab, recently approved worldwide. CASE PRESENTATION: A 75-year-old Caucasian man presented to our hospital with severe aphasia and mild hemiparesis. After providing written consent, he received two doses of 2.5 g of idarucizumab over 20 minutes followed by standard protocol in-label recombinant tissue plasminogen activator application. All symptoms resolved within 1 h. CONCLUSIONS: Applying a recombinant tissue plasminogen activator after antagonizing dabigatran with idarucizumab is feasible and easy to manage in an emergency room or stroke unit. Thus, idarucizumab represents a new therapeutic option for patients receiving dabigatran treatment, reestablishing their eligibility for recombinant tissue plasminogen activator thrombolysis.
9
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
Stuart J. Connolly, Michael D. Ezekowitz, Salim Yusuf et al. · New England Journal of Medicine · 2009 · 11.2K citations · Full text
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel, Kenneth W. Mahaffey, Jyotsna Garg et al. · New England Journal of Medicine · 2011 · 9.4K citations · Full text
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger, John H. Alexander, John J.V. McMurray et al. · New England Journal of Medicine · 2011 · 8.9K citations · Full text
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
Robert P. Giugliano, Christian T. Ruff, Eugene Braunwald et al. · New England Journal of Medicine · 2013 · 5.1K citations · Full text
Idarucizumab for Dabigatran Reversal
Charles V. Pollack, Paul A. Reilly, John W. Eikelboom et al. · New England Journal of Medicine · 2015 · 1.5K citations